Jco precision oncology.

DOI: 10.1200/PO.21.00437 JCO Precision Oncology no. 6 (2022) e2100437. Published online January 27, 2022. Published online January 27, 2022. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature …

Jco precision oncology. Things To Know About Jco precision oncology.

OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic …15 Mar 2023 ... Elypta study published in JCO Precision Oncology using GAGome to predict and monitor responses of patients with Metastatic Renal Cell ...DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812. Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials Enrique Sanz-Garcia, MD, PhD 1. x. Enrique Sanz-Garcia. Search for articles by …WebDOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 201715 Mar 2023 ... Elypta study published in JCO Precision Oncology using GAGome to predict and monitor responses of patients with Metastatic Renal Cell ...

Feb 6, 2019 · DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019 Jan 12, 2023 · PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ...

Precision fabrication is a critical process in various industries, including manufacturing, construction, and automotive. Whether it’s building structures, creating intricate metal designs, or repairing equipment, welding plays a crucial ro...

Diagnosis & treatment of ercc3-mutant cancer US20210137850A1. Other Relationship: AnaNeo Therapeutics. Jinru Shia. Consulting or Advisory Role: PAIGE.AI. Zsofia K. Stadler. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.By July 20, 2020, 20 patients with TRK fusion–positive lung cancer had been treated. The ORR by investigator assessment among 15 evaluable patients was 73% (95% CI, 45 to 92); one (7%) patient had a complete response, 10 (67%) had a partial response, three (20%) had stable disease, and one (7%) had progressive disease as best response. DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsApr 1, 2021 · Multicancer Screening: One Size Does Not Fit All. Cancer is the second leading cause of death in the United States, 1 and early detection represents one of the best hopes for reducing cancer-associated morbidity and mortality. However, current screening strategies are limited by suboptimal adherence, low sensitivity for early-stage disease ...

Professional English and Academic Editing Support. Submit to JCO PO. View/Change User Info. Institutions and Librarians. Subscribe to this Journal. Journal of Clinical Oncology. JCO Oncology Practice. JCO Global Oncology. JCO Clinical Cancer Informatics.

PURPOSE To develop and validate a cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk. We hypothesized that the caIRS is a better predictor of BC risk than clinical risk factors across diverse ancestry groups. METHODS We used diverse retrospective cohort data with longitudinal follow-up ...

Jan 14, 2021 · DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome DOI: 10.1200/PO.18.00299 JCO Precision Oncology - published online April 25, 2019 PMID: 32914040 Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung CancerJul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... DOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed to provide the best quality. The journal welcomes submissions from the research community where emphasis will be placed on the originality and the practical impact of the reported research.DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyDOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994

The 2022 impact factor of JCO Precision Oncology is 3.6, making it among the top 4% journals. The journal covers the disciplines of Oncology.DOI: 10.1200/PO.20.00037 JCO Precision Oncology no. 4 (2020) 757-766. Published online June 25, 2020. PMID: 35050752. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study Eugene R. Ahn, MD 1. x. Eugene R. Ahn ...Web24-hour private clinics and medical centers 49 Ambulatory surgery in Tashkent, in Uzbekistan 4 Analyses of blood by rubella - services 3 Analysis of allergy - services 7 …Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. ... JCO Precis Oncol. 2019 Dec …Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, 1 is a group of heterogeneous diseases driven by a spectrum of molecular alterations. Targeted therapies directed toward specific molecular alterations, such as a mutation in epidermal …When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...

Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ...

DOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...DOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...Jan 14, 2021 · DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome PURPOSE Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The ...Apr 26, 2023 · PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ... PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ...

Professional English and Academic Editing Support. Submit to JCO PO. View/Change User Info. Institutions and Librarians. Subscribe to this Journal. Journal of Clinical Oncology. JCO Oncology Practice. JCO Global Oncology. JCO Clinical Cancer Informatics.

PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of HER2-altered NSCLC in an Asian tertiary cancer center. METHODS ...

PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the use of these drugs in children. This systematic ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic …Jun 29, 2023 · Cutaneous melanoma (CM) is the fifth most common cancer in the United Sates, with an estimated 99,780 new cases diagnosed in 2022. 1 Prognostic biomarkers aim to identify patients at high or low risk of disease progression to align treatment decisions with the risk of poor outcomes. 2,3 For CM, the most well-established prognostic markers outlined by the American Joint Committee on Cancer ... Jan 8, 2021 · DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations Multicancer Screening: One Size Does Not Fit All. Cancer is the second leading cause of death in the United States, 1 and early detection represents one of the best hopes for reducing cancer-associated morbidity and mortality. However, current screening strategies are limited by suboptimal adherence, low sensitivity for early-stage disease ...22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic ProfilingWebDOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsWebJCO Precision Oncology 10.1200/PO.17.00071 (2017). Google Scholar. Yoshida, G.J. Applications of patient-derived tumor xenograft models and tumor organoids ...DOI: 10.1200/PO.23.00261 JCO Precision Oncology no. 7 (2023) e2300261. Published online October 12, 2023. PMID: 37824797. Computational Advancements in Cancer Combination Therapy Prediction Victoria L. Flanary, BS 1. x. Victoria L. Flanary. Search for articles by this author ...Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP… ... EACH PATIENT IS NOTABLE AND CAN BENEFIT FROM A PREDICTIVE PRECISION MEDICINE ...DOI: 10.1200/PO.21.00283 JCO Precision Oncology no. 6 (2022) e2100283. Published online May 25, 2022. PMID: 35613412. Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion Anne Thorwarth, MD 1. x. Anne Thorwarth ...

Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ... DOI: 10.1200/PO.16.00066 JCO Precision Oncology - published online June 27, 2017WebThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …Instagram:https://instagram. vanguard total stock market index etfcorvextrade crypto webullhow to sell stocks on etrade Manuscripts Involving Precision Oncology. JCO appreciates the potential value of studies addressing the role of precision oncology in selecting optimal therapy for patients with cancer. Many such studies have already been published, showing the feasibility of performing large scale molecular testing such as Next Generation … crypto exchange with debit cardsugar free prosecco Aug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ... nividia earnings DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryPurpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …